Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 20, 2005. The report details specific corporate actions regarding share repurchases and changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific share transaction:
- Share Repurchase Price: 1,351.45 pence per share.
- Shares Purchased: 700,000 Ordinary Shares.
- Treasury Shares Held: 90,783,000 (post-transaction).
- Shares in Issue: 5,851,686,178 (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a treasury buyback executed on May 19, 2005. Additionally, the GSK Trust transferred 3,720 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It strictly reports on the execution of share buyback authority granted at the Annual General Meeting on May 17, 2004.
Key Facts for Investor Verification
- Verify the total cost of the 700,000 share repurchase (700,000 shares x 1,351.45 pence).
- Confirm the updated total share capital structure (5,851,686,178 shares in issue plus 90,783,000 treasury shares).
- Note that three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold indirect interests via the GSK Trust.
- Understand that this filing does not contain operational or financial performance data for the period.